Decision Quality: A Key Source of Competitive Advantage in Drug Development
Poor decision quality has the potential to undermine the hard-won benefits of rationalization efforts and constitutes an under-exploited source of competitive advantage, says Boston Consulting Group.
You may also be interested in...
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.